Table 2.

Univariate logistic regression analysis of factors affecting LPE efficacy.

	HR	95% CI	P -value
Age ≥ 50 years	0.383	0.163–0.896	0.027*
Gender (male)	0.629	0.273–1.447	0.275
Course of disease	1.003	0.996–1.010	0.401
Thymoma	1.027	0.368–2.868	0.959
Thymic hyperplasia	0.967	0.097–9.657	0.977
Thymectomy	0.753	0.292–1.945	0.558
Coexistence with other autoimmune diseases	2.625	0.724–9.517	0.142
Co-infection	0.274	0.115–0.654	0.004**
Immunotherapy before treatment	1.214	0.533–2.768	0.644
History of myasthenic crisis	1.207	0.313–4.651	0.784
MGFA classification (IVb)	1.203	0.423–3.418	0.729
Baseline QMG score	0.980	0.890–1.080	0.690
AChR-Ab	0.532	0.111–2.551	0.430
MuSK-Ab	0.967	0.097–9.657	0.977
Titin-Ab	0.660	0.253–1.722	0.396
RyR-Ab	5.139	0.647–40.846	0.122

HR, Hazard ratio; 95% CI, 95% confidence interval;

^*p < 0.05,

^**p < 0.01.